Robin Foà, MD, Sapienza University of Rome, Rome, Italy, describes the ways in which measurable residual disease (MRD) could play a role in follicular lymphoma (FL), even though it is not currently a recommended endpoint of treatment. Prof. Foà also comments on MRD detection and monitoring techniques including quantitative PCR (qPCR), digital droplet PCR, and liquid biopsy. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.